-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mozafancogene Autotemcel in Fanconi Anemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mozafancogene Autotemcel in Fanconi Anemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mozafancogene Autotemcel in Fanconi Anemia Drug Details: RPL-102 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sotagliflozin in Hypertrophic Cardiomyopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sotagliflozin in Hypertrophic Cardiomyopathy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sotagliflozin in Hypertrophic Cardiomyopathy Drug Details: Sotagliflozin (Zynquista, Inpefa) is a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Imzokitug in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Imzokitug in Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Imzokitug in Melanoma Drug Details: imzokitug (BMS-986340) is under development for the...
-
Company Insights
NewDecoding Enel S.p.A. YouTube Advertising Strategy in Q1 2024​
The report on Enel S.p.A's advertising strategies on YouTube during the first quarter of 2024, focuses on key products such as Enel Formidable Photovoltaic and Enel Formidable Mobility. It analyzes the core themes, messaging strategies, and product benefits portrayed in these advertisements, highlighting elements such as Renewable Energy, Energy Storage, Solar Park and Energy Production. Moreover, the report examines the overarching themes of Innovation, Community Engagement, Social Responsibility, Environmental Impact and Clean Energy infused into these campaigns. By synthesizing these...
-
Analyst Opinions
NewBeyond Bytes – Data Center Evolution for Peak Performance
Beyond Bytes – Data Center Evolution for Peak Performance Report Overview The data center and hosting services market size was valued at $107 billion in 2023. The data center services market growth will be driven by the emergence of Generative AI (genAI). Furthermore, a surge in digital content and rapid cloud adoption are a few of the other drivers that will propel the data center services market to register a CAGR of more than 12% from 2023-2027. Data Center and...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ECT-001 in Myelodysplastic Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ECT-001 in Myelodysplastic Syndrome report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ECT-001 in Myelodysplastic Syndrome Drug Details: ECT-001 cell therapy is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Curcumin + Doxorubicin) in Leiomyosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Curcumin + Doxorubicin) in Leiomyosarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Curcumin + Doxorubicin) in Leiomyosarcoma Drug Details: Imx-110 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ELX-02 in Cystic Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ELX-02 in Cystic Fibrosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ELX-02 in Cystic Fibrosis Drug Details: ELX-02 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AFM-24I in Metastatic Hepatocellular Carcinoma (HCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AFM-24I in Metastatic Hepatocellular Carcinoma (HCC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AFM-24I in Metastatic Hepatocellular Carcinoma (HCC) Drug Details: AFM-24I...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – INBRX-106 in Gastrointestinal Stromal Tumor (GIST)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - INBRX-106 in Gastrointestinal Stromal Tumor (GIST) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. INBRX-106 in Gastrointestinal Stromal Tumor (GIST) Drug Details: INBRX-106...